Join the Oncology Voice Network. Join for Free
How to Prepare a Presentation for an MSL Interview with Kathy Gann
MSL interview preparation presentation tips MSL director insights interview advice Mallinckrodt and Syneos Health

How to Prepare a Presentation for an MSL Interview with Kathy Gann


Share This Article


Summary

In this episode, my guest is Kathy Gann. Kathy is a former MSL director of Mallinckrodt and Syneos Health and we talk about how to prepare a presentation for an MSL interview. Great information so anyone preparing for an interview should check this out.

In this episode:

  • Expect the unexpected
  • Three types of presentation
  • What are the interviewers listening for?
  • How much practice is required to ensure a GOOD presentation?
  • Advice for someone who gets a question they don’t have the answer
  • Interesting interview stories of presentations gone bad
  • Kathy’s advice for aspiring MSL candidates?

Click for Source
MSL interview preparation, presentation tips, MSL director insights, interview advice, Mallinckrodt and Syneos Health

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How I landed my first MSL role... what works, what doesn't, and what you need to know
Partner Avatar MSL Talk: Tom Caravela, Julie Chen

How I landed my first MSL role... what works, what doesn't, and what you need to know

Podcast
How to Prepare and Succeed on a Video Interview
Partner Avatar MSL Talk: Tom Caravela, Laura Wilson, MD

How to Prepare and Succeed on a Video Interview

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN